In a previous randomized study, we showed that adjuvant immunotherapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 (rIL-2) significantly improved survival in resected N2-Non Small Cell Lung Cancer (NSCLC) patients. The present study assesses feasibility, safety and potential efficacy of combined neo-adjuvant chemotherapy and immunotherapy with peripheral blood mononuclear cells (PBMC) and rIL-2 in resectable N2-NSCLC patients. Eighty-two consecutive N2-NSCLC patients underwent neo-adjuvant chemotherapy with cisplatin and gemcitabine. Out of the 82 patients, 23 were also subjected to leukapheresis prior to neo-adjuvant chemotherapy while the remaining 59 did not. Collected PBMC were analyzed for viability and phenotype and then stored frozen in liquid nitrogen. Thawed PBMC were infused intravenously, 5 days before surgery. After the infusion, rIL-2 was administered subcutaneously until surgery. Only patients with a partial or complete response to neoadjuvant chemotherapy underwent surgery: 13 patients in the experimental immunotherapy group (A) and 32 in the reference group (B). The two groups were homogeneous for all major prognostic factors. Median leukapheresis yield was 10 billion PBMC, (range 3-24 billions). Two to six billion PBMC were infused. The phenotypic analysis showed that similar proportions of CD4 and CD8 cells were present in leukapheresis products, and thawed PBMC, as well as in T lymphocytes isolated from the removed tumours. No severe adverse effects were observed following immunotherapy. No significant differences in overall survival (OS) and event-free survival (EFS) were seen between the two groups. However, the 5-year OS in group A was almost twice as much compared to group B (59% vs 32%). After adjustment for major prognostic factors, a statistically significant 66% reduction in the hazard of death was seen in patients receiving immunotherapy. The OS benefit was more evident in patients with adenocarcinoma than in those with squamous cell carcinoma. This study supports the favorable toxicity profile and potential efficacy of combining neo-adjuvant chemotherapy and immunotherapy with PBMC and rIL-2 in the treatment of N2-NSCLC patients.
In spite of recent improvements in treatment, the majority of patients with N2-Non Small Cell Lung Cancer (NSCLC) ultimately will relapse and die from their disease. Thus, several novel strategies for the treatment ofN2-NSCLC are currently under evaluation. We previously published the results of a randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes (TIL) and recombinant interleukin-2 (r-IL-2) versus standard chemotherapy in the post-operative treatment of resected N2-NSCLC (I). Subsequently, in an attempt to improve the results of adjuvant immunotherapy with TIL and rlL-2, we combined chemotherapy, immunotherapy and radiotherapy in the post-operative treatment of patients with stage III-NSCLC (2) . While the results of the former were promising, those of the latter were negative. Nevertheless, other groups studied different immunotherapeutic approaches. Following the pioneering studies on immunotherapy of lung cancer (3), Kimura et al. (4) conducted a prospective phase II study of chemo-immunotherapy using activated killer T cells and dendritic cells. In a multicenter phase IlB randomized trial, Butts et al. (5) (6) used the liposomal MUC I vaccine L-BLP25 following chemotherapy or chemo-radiotherapy in patients with non-progressive stage IIIB or IV NSCLC. In another multi-center, double-blind, randomized, placebo-controlled phase II study, Vansteenkiste et al. (7) tested the activity of MAGE-A3 as adjuvant therapy in completely resected stage IB or II NSCLC patients. Although suggesting a potential effect of combining chemotherapy with immunotherapy, all these studies did not produce clear and, most of all, definitive results.
Notably, unpublished data from our laboratory showed that the proliferative and functional capacities of TIL isolated from NSCLC of patients who underwent neo-adjuvant chemotherapy were severely damaged, making it impossible to recruit and expand adequate numbers of functional TIL. Thus, the above-mentioned adjuvant immunotherapy (I) was unfeasible in nee-adjuvant chemotherapy treated patients. For this reason, we designed the present pilot study to assess the feasibility, safety and potential usefulness of combining neo-adjuvant chemotherapy and immunotherapy with peripheral blood mononuclear cells (PBMC) and r1L-2, in resectable N2-NSCLC patients. This approach was based on the hypothesis that lymphocytes collected before chemotherapy might preserve their proliferative and functional properties, maintaining, after infusion before the surgical treatment, the ability to restore the impaired immunological competence in patients treated with chemotherapy. Furthermore, leukapheresis, lymphocyte freezing and thawing, as well as the infusion of unmodified autologous cells are safe procedures, routinely used in hematological and oncological practices.
MATERIALS AND METHODS

Patient population
From 2002 to 2005, 82 consecutive patients with N2-NSCLC were enrolled in the study. The protocol was approved by the Ethics Committee of Regione Piemonte (Italy). All patients were informed of the aims and procedures of the study and signed a consent form.
Pre-operative assessment included: CT scan of the brain, chest, and upper abdomen; bronchoscopy; PET scan; and cervical mediastinoscopy. Inclusion criteria were: mediastinoscopic demonstration of N2-NSCLC; absence of distant metastases; disease considered completely resectable; cardiopulmonary, hematologic, renal and hepatic functions adequate for the planned treatment; performance status (PS) 0-1; no prior therapy with biological response modifiers , anti-neoplastic agents or steroids.
Study design, treatment andfollow-up
The process of selection of the study population is summarized in Fig. I . All 82 patients received 3 cycles of induction chemotherapy with cisplatin and gemcitabine. Among these patients, 23 agreed to undergo subsequent neo-adjuvant immunotherapy and underwent leukapheresis before starting neo-adjuvant chemotherapy. Among the other 59 patients, 6 refused the experimental immunotherapy and 53 could not undergo leukapheresis because of laboratory unavailability. These 59 patients were included in the study as reference to allow comparison of overall survival (OS) and event-free survival (EFS) for merely exploratory purposes.
Only patients who showed either a partial or a complete response to the mediastinum and no tumor progression after neo-adjuvant chemotherapy (as documented by CT scan and PET scan) underwent surgery and represent the study population: 13 out of the 23 (57.0%) patients who underwent leukapheresis and subsequent immunotherapy (experimental group A) and 32 out of the 59 (54.3%) immunologically untreated patients (reference group B). Of the remaining patients, lOin group A and 27 in group B, who showed either no response to neo-adjuvant chemotherapy or disease progression were not surgically treated.
In the 13 responders of the experimental group A, thawed PBMC (2 to 6 billion cells) were infused intravenously five days before surgery. This period was defined on the basis of the capacity ofthawed lymphocytes to remain in lung tissues (8) .
Thereafter, rlL-2 was administered subcutaneously (3 million IV per mvday) for the next 4 days. The same oncological and technical principles were applied for each surgery. Tumor resection was classified as complete (RO), microscopically incomplete (RI), or macroscopically incomplete (R2) . Complete mediastinal lymph node dissection was carried out in all cases, as previously described (9) (10) . A small fragment of tumor was also processed in the laboratory as previously descr ibed (II) in order to establish whether a locoregional immune response had been induced by neoadjuvant immunotherapy. Lymphocyte populations and subpopulations were analyzed using immunophenotyping and flow cytometry, as described below. Follow-up included physical examination, routine blood tests and tumor marker evaluation (CEA , CYFRA and NSE) every 4 months, chest X-ray every 6 months, and CT scan of the chest and upper abdomen every year unless a relapse was suspected earlier. PET scan was used to document a tumor relapse suspected on the basis of CT images .
Leukapheresis and processing of peripheral blood mononuclear cells
Leukapheresis was performed using the standard procedure. Blood was drawn from peripheral veins. Leukocytes were collected through a continuous-flow blood cell separator (Cobe Spectra; Gambro BCT Europe, Zaventem, Belgium), operating a software version 6.1 Auto PBSC. Acid citrate dextrose (ACD-A) was used as anticoagulant for whole blood (anticoagulant ratio 13.5-14: I) . Isolated cells were analyzed and differential cell counts were computed using a Bayer Advia 120 blood cell analyzer. PBMC were also evaluated for the presence of lymphocyte populations and subpopulations using flow cytometry (Becton Dickinson FACSaria) and a panel of fluorochrome-labeled monoclonal antibodies specific for lymphoid antigens. These included CD45, CD2, CD3, CD4, CD8, CDl6, CD 19, CD20 , CD25, CD56 , CD69 and HLA-DR (Coulter-Beckman).
Mononuclear cells were stored frozen in liquid nitrogen in cryovials at the median concentration of 64 million cell/ml in saline solution supplemented with human serum albumin (30% v/v) and DMSO (10% v/v). Before infusing cells, cryovials were thawed at 3rC and DMSO was removed by centrifugation. Dead cells were also removed using a discontinuous Ficoll-Paque gradient. The cells were then harvested from the interface, counted, and diluted in 500 ml buffered saline solution supplemented with 20% human serum albumin. The washing procedure was required because the clinical unit where the infusions were performed, was several kilometers away from the laboratory. Nevertheless, the procedure had been previously validated in a similar clinical setting (12) . Quality controls of the frozen product included biosafety (absence of bacteria, fungi, mycoplasmas and endotoxins), and cell viability. A phenotypic analysis was also performed on thawed cells as described (12) .
Statistical analysis
All eligible patients who underwent surgery were included in the analysis. The primary aim of the study was the assessment of the feasibility and safety of the experimental treatment. Secondary aims were the evaluations of overall survival (OS) and event-free survival (EFS). These additional aims were included merely for exploratory purposes. Overall survival was estimated from the date of surgery to the date of last contact or death from any cause. Event-free survival was estimated from the date of surgery to the date of occurrence of any event including local relapse , controlateral primary tumor, distant relapse or death from any cause , whichever came first. Differences between the two groups in baseline prognostic factors were assessed by the Pearson chi-square test. OS and EFS were obtained from Kaplan-Meier analyses, and the primary comparison between the two groups was carried out using the log rank test. For each prognostic factor, stratified univariate analyses and log rank tests were also used to assess statistical differences between the two treatment groups. Cox's model was used for multivariate analyses to assess the independent prognostic role of each prognostic factor, while adjusting for the effect of the other factors. The variables included in the models as covariates were : patient's age (:::::60 years , 61-65 years , >65 years), gender, tumor histology (squamous carcinoma, adenocarcinoma), pathological T (pTO, pTI, >pT I), tumor grade (GI or G2, G3), nodal status (NO, N2) and immunotherapy. Hazard ratios (HRs) for each variable were obtained by exponentiating the coefficients estimated by the Cox 's models. Modifications of the relative effect of neoadjuvant chemo/immunotherapy as compared to standard nco-adjuvant chemotherapy across the strata of each covariate were assessed by introducing the appropriate interaction terms in the model. These covariates by treatment interaction terms were introduced in the model one at a time. The likelihood ratio test was used to evaluate the statistical significance of each interaction term. All statistical analyses were two-sided and were performed using the SPSS package (version 16.0 for Windows).
RESULTS
Patients characteristics
Of the 45 patients selected for statistical analyses, 13 underwent neo-adjuvant chemotherapy and immunotherapy. The other 32 patients received chemotherapy alone and were used as a reference.
Overall, the median observation time between surgery and death or censoring was 3.7 years. Nineteen patients (42%) were alive at the end of the study with a median follow-up of 4.8 years (4.3 years for group A and 5.2 years for group B). Among these patients, 14 (74%) were free of disease and 5 (26%) were not. Other 17 (38%) patients went in progression and died thereafter. Overall, an event (relapse or death) was recorded for 31 patients (69%).
Patient and tumor characteristics are summarized in Table I . For each prognostic factor, patient distribution between subgroups was rather homogeneous, except for tumor grade: G3 disease was more often found in group A (p=0.012). Noteworthy, more than half of the patients (n=25, 55.6%) benefited from the induction chemotherapy, down-staging from pre-induction N2 to postinduction NO: 7 in group A and 18 in group B.
Leukapheresis results and immunological evaluation
Leukapheresis processed 6500 (range 5550- ... 6866) ml of blood from patients (median weight 72 kg ; range 51-84 kg). The median peripheral blood leucocyte count was 104 x l 09 cells /L (range 40-220), with a percentage of peripheral blood mononuclear cells (PBMC) of 28 (range 14-42). Median leukapheresis time was 130 minutes (range 120-185) at a flow rate of 53 ml/min (range 50-56) Leukaphereses had a good yield (median 10 billion PBMC; range 3-24 billions). The percentage of lymphocytes was high (72%, range 61-95%). After thawing, a median of 4 billion PBMC (range 2-6 billions) was infused . In these samples, the percentage of lymphoid cells was also high (85%, range 79-100%). The phenotypic analysis showed that a variable proportion of CD4 and CD8 , as well as activated lymphocytes , was present. A similar proportion was observed in T lymphocytes isolated from the removed tumor. Notably, both Band NK cells were virtually absent in samples collected from the tumor site, while T cells expressing either the "helper" or the cytotoxic phenotype were constantly detected (Table II) . In tumor samples obtained from patients treated with neo-adjuvant chemotherapy alone , T cells were absen t.
Feasibility and safety ofthe experimental therapy
The planned treatm ent was completed without any significant side effect in the 13 patients of the group A. No adverse reaction was observed following PBMC infusion. Minor symptoms, such as fever, related to rIL-2 administration were easily controlled with appropri ate drugs When the comparison between the two groups was adjusted for age, gender, tumor histo logy, tumor grade, pT and nodal statu s (Table III) , no statistically significant differences were observed with respect to either as or EFS .
Multivariate and subgroup analyses
In multivariate analyses, gender, tumor histology, and nodal status were independently associated with as and /or EFS (Table IV) . Patient age, tumor grade and pathological T were not, although an association of borderline significance of the latter two with EFS was observed (p=0.07 I for tumor grade and 0.066 for pT) . After adjustment for all these prognostic factors , a statistically significant 66% reduction in the hazard of death was found and it was associated with the immunotherapy treatment (HR = 0.34, 95% CI O. I2-1.0; p=0.034 ). The effect on EFS was less Subgroup anal yses of as and EFS comparing group A versus group B with in strata formed by each prognostic factor, showed no evidence of associ ation between the type of treatment and patient age, gender, tumor grade, pT and pN (p of interaction ranging from 0.216 to 0.915). By contrast, in terms of as, we found a different treatment effect between patients with squamous cell carcinoma and those with adenocarcinoma ( Fig. 3 ). In patients with squamous cell carcinoma, 5-year as was 37% (95% CI = 33-40) in group Band 33% (95% CI =30-36) in group A (p=0.494). Conv ersel y, in patients with adenocarcinoma, 5-year as was 30% (95% CI = 27-33) in group Band 86% (95% CI = 83-88) in group A (p of interaction = 0.041 ).
DISCUSSION
Stage IIIA-N2 NSCLC represents the most therapeutically challenging and controversial sub set of lung cancer (13) . This heterogeneous group of patients has been the subject of many clinical trials , indicating that a combined modality approach is the most beneficial treatment (14) . In spite of recent impro vements in treatment modalities, long term survival in pre-operatively diagnosed N2-NSCLC patients remains poor. Consequently, there is an urgent need for novel therapeutic strategies. Immunotherapy may reasonably be included among these approaches (\ 5).
To our knowledge, this is the first study to investigate the feasibility and potential usefulness of immunotherapy with PBMC and rIL-2 in the neo-adjuvant treatment of patients with resectable, pre-operatively diagnosed, N2-NSCLC. While interpreting the results ofour study, we are aware that many fundamental questions remain unanswered: the effects ofchemotherapy regimens on the immune system are largely unknown or unexpected (16) and a clear understanding of the mechanisms of our immunological approach is lacking. Nevertheless, when the phenotypic analysis of T cells infiltrating the tumours in group A was compared with that of group B, a clear difference was observed. Indeed, while T cells were virtually absent in patients who did not undergo immunotherapy, these cells were detectable in the samples of patients recei ving thawed lymphocytes before surgery. Along this line , it should be noted that the significant reduction of cancer mass following neo-adjuvant chemotherapy had completely forbidden any attempt to evaluate the capacity oflymphocytes derived from resected tissue to lyse autologous tumor cells.
We must acknowledge that this is a nonrandomized study, underpowered to detect significant differences. Nevertheless, both group A and group B were based on a homogeneous and a highly selected group of patients. It is common knowledge that N2-NSCLC includes subsets of patients with different prognoses and therapeutic options. The present study enrolled only patients with pre-operatively demonstrated N2 disease, who were judged completely resectable and showed a response to induction therapy at the mediastinal node level. Excluded from the study were patients with intraoperatively or post-operatively detected mediastinal node metastases, as well as those with stable or progressive disease after induction chemotherapy. Furthermore, in all patients, the N3 status was excluded by pre-induction mediastinoscopy, while the response to induction therapy was routinely assessed by both CT and PET scan.
Keeping in mind the above-mentioned drawbacks, the present study shows that, for patients with resectable N2-NSCLC, the neo-adjuvant treatment including chemotherapy and immunotherapy with PBMC and rIL-2 is feasible and well tolerated. These results fulfill the primary aim of the study in that the neo-adjuvant chemo/immunotherapy procedure appears to be safe. In addition, when analyzing the outcome of all patients included in the study merely for exploratory purposes, a statistically significant reduction ofthe hazard ofdeath was found in patients recervmg chemotherapy and immunotherapy, in respect to those who underwent chemotherapy alone. Five-year OS in group A was almost twice as much compared to group B. Although they are rather promising, these results have to be confirmed in further randomized trials based on large patient numbers. The favorable effect of neo-adjuvant immunotherapy was not observed when considering the event-free survival. The discrepancy between the OS and the EFS curves may result 1) from the small number of patients in the neo-adjuvant chemo/ immunotherapy group, 2) from the presence, in this group, of three patients who survived with disease recurrence; the survival of these patients may be due to their rather young age (56 , 62 and 64 years) and/or to the fact that their respective post-event observation period was rather short, the relapse occurring at 11, 16 and 38 months from the end of the overall 6-year period of the study. An additional interesting finding, requiring further investigation but potentially based on experimental evidence (17) , is the different efficacy of immunotherapy between patients with squamous cell carcinoma and those with adenocarcinoma. In patients with squamous cell carcinoma, 5-year OS was similar in group A and in group B. Conversely, immunotherapy showed a higher efficacy in patients with adenocarcinoma, the 5-year OS being 86% in group A and 31% in group B.
In conclusion, the favorable toxicity profile of neo-adjuvant immunotherapy with PBMC and r1L-2 maintains the promise of improved tolerance and efficacy of combined induction regimens in patients with resectable N2-NSCLC. The results of the present study are in line with those of previous studies using different immunologic approaches both in the neo-adjuvant and adjuvant treatment of N2-NSCLC patients. Since all these studies support the potential efficacy of immunotherapy, this approach should be considered when planning future combined therapeutic regimens. In addition, the regimen proposed here can be easily carried out even in centers which are not highly specialized, because of the widespread use of leukapheresis and the low cost of this procedure.
However, before starting a phase III study aimed to assess the value of induction immunotherapy with PBMC and rIL-2 in a larger number of N2-NSCLC patients, further knowledge on the interaction between chemotherapy agents and the immune system, as well as a better understanding of the effects of immunotherapy are required.
